Economic Burden Attributable to Healthcare-Associated Infections in Tertiary Public Hospitals of Central China: A Multi-Center Case-Control Study

Peng Li  
Henan Provincial People's Hospital

Yan Li  
Henan Provincial People's Hospital

Youjian Zhang  
Henan Provincial People's Hospital

Junzhe Bao  
Zhengzhou University

Ruixia Yuan  
Zhengzhou University First Affiliated Hospital

Hongwen Lan  
Wuhan Union Hospital

Mingjie Sun ({lpsxjlp@whu.edu.cn})  
Henan Provincial People's Hospital  https://orcid.org/0000-0003-3320-4280

Research

Keywords: healthcare-associated infection, economic burden, tertiary public hospital, China

DOI: https://doi.org/10.21203/rs.3.rs-676716/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Healthcare-associated infection (HAI) is a major cause of morbidity, mortality and cost, which vary widely by region and hospital. We aimed to calculate losses attributable to HAI in central China.

Methods

We performed a three-stage random sampling and employed a 1:1 matched case-control study in tertiary public hospitals of Central China. The direct medical cost attributable to HAI was calculated, and then compared among different types of HAIs by employing a subgroup analysis.

Results

A total of 2976 patients in 10 hospitals were enrolled, and the incidence rate of HAI (range, 0.88%-4.15%) was significantly, but negatively associated with the cost per 1000 beds of its prevention (range, $24929.76-$53146.41; r=-0.76). The per capita economic loss attributable to HAIs was $2047.07 (interquartile range, $327.63-$6429.17), mainly from the pharmaceutical cost (median, $1044.39). The HAIs, which occurred in patients with commercial medical insurance, affected the hematologic system and caused by A. baumannii, contributed most to the losses (median, $3881.55, $4734.20 and $9882.75, respectively), and a significant correlation existed between the economic loss and age (r=0.26). Furthermore, the economic losses attributable to device-associated infections and hospital-acquired multi-drug resistant bacteria were 2 to 4 times those of the controls.

Conclusions

The economic burden attributable to HAI in central China is heavy, and opportunities for easing this burden exist in several areas, including that strengthening antibiotic stewardship and practicing effective bundle of HAI prevention for patients carrying high risk factors, for example, elders or those with catheterizations in healthcare institutions, and accelerating the medical insurance payment system reform based on Diagnosis Related Groups (DRGs) by policy-making departments.

Background

Healthcare-Associated Infection (HAI) occurs with the founding of hospital, which is characterized by high morbidity and mortality [1]. And it is not only life-threatening and increases burden on individuals and families, but also causes huge resource wastes and economic losses for hospitals and society. The cumulative burden of HAIs was about 501 disability adjusted life years per 100,000 population each year, which was higher than the total burden of all other 32 kinds of diseases included in the Burden of Communicable Diseases Project in Europe [2]. In the United States, 1.7 million people suffer from HAIs every year, which causes an economic loss of $8.3 billion to $11.5 billion [3]. The impacts HAI has on patients [4], hospitals [5] and society [6] are well recognized, while most of them focused on high-income
countries (HICs). What is worth mentioning, the low- and middle-income countries (LMICs) have limited medical resources but high incidences of HAIs, resulting in relatively larger incidence of patient disability, mortality and additional hospitalization cost [7]. However, the burden attributable to HAIs in LMICs remains poorly defined compared with that in HICs. Moreover, due to the objective factors vary, such as the demographic and sociological characteristics, medical insurance policies, economic development levels and hospital scales, the existed health economic characteristics of HAIs may not have universal applicability and cannot be generalized to another hospital, country or region as a whole. Incidentally, As one of the most populous and medical resources scarce provinces, Henan Province has about 109 million population, one third of the population of Central China, and 19 million discharged patients in 2018 [8], where there has been no research focusing on exploring the health economic characteristics of HAIs because of the absence of representative data. We therefore conducted a multicenter, retrospective, standardized case-control study, to accurately estimate the current economic burden of HAIs in tertiary public hospitals of Central China, and to provide data support and factual evidence for further research and policy making.

Methods

Patients and study design

We adopted a three-stage random sampling method to select patients with HAIs in tertiary public hospitals of Henan Province. In the first stage, based on the economic level, all 18 cities were ranked by their Gross Domestic Product (GDP) in 2018, and the first of every three cities was chosen. In the second stage, according to the number of tertiary public hospitals of the included cities and their feasibility of conducting this survey, one or more hospitals were selected in each city by using stratified sampling. In the last stage, with a systematic sampling strategy, all patients suffered from HAI in the selected hospital between January 1 and December 31 2018 were ranked by their admission numbers, and the first of every seven patients was selected into the HAI group.

Then we designed the study to have 1:1 matching, with one control who did not suffer from HAI for each case. In order to reduce the confounding bias caused by undermatching or overmatching, controls were selected according to the following matching criteria: (1) the first discharge diagnoses were same, coded by the International Classification of Diseases, 10th Revision (ICD-10, Version: 2016); (2) the age-adjusted Charlson Comorbidity Index (aCCI) were equal; (3) the surgeries undergone were same, coded by the ICD Clinical Modification of 9th Revision Operations and Procedures (ICD-9-CM-3); (4) the gender were same; (5) the age gap was 5 years or less, and no more than half a year for children under 5 years old; (6) The inpatient departments were same; and (7) the difference of admission date was a month or less. Patients with length of stay (LOS) ≤ 2 days were excluded, and if there was more than one patient without HAI meeting the above matching criteria, selected the one who had smallest age gap with infected patient into the control group. The HAIs were diagnosed according to the Diagnostic Criteria for Nosocomial Infection, which was published by the National Health Commission of China in 2001 [9]. The study
conforms to the ethical principles of the 2013 revised Declaration of Helsinki and received the Ethic Committee approval from all of the surveyed hospitals, with a waiver for patient informed consent.

Data collection

The hospitalization cost, demographic and clinical characteristics of patients were retrieved from the Hospital Information System, and the epidemiological characteristics of HAIs were obtained from the Nosocomial Infections Surveillance System (NISS) of the selected hospitals. The cost of infection prevention and control (IPC) was collected through field questionnaire surveys, which mainly comprises office expenses, labor cost of full-time and part-time staff, NISS maintenance fee, funds of activities such as training, seminar and so on. The discharge diagnoses were retrieved from the home page of electronic medical records, and the aCCI was calculated by weighting each condition to assess the aggregate burden of comorbidity [10]. The detailed calculations of hospitalization cost, IPC cost and economic loss attributable to HAI are shown in the Appendix. The average exchange rate of CNY (¥) to USD ($) was 6.86:1, issued by The People’s Bank of China from the period over which the study took place.[11] An investigator-unified training was conducted before the survey, and data validation was performed with double entry in the process of data extraction.

Statistical analysis

We used EpiData 3.1 (EpiData Association, Odense, Denmark), Excel 2010 (Microsoft Corporation, Seattle, Washington, USA) for data collection and mining, and SAS 9.4 (SAS Institute, Cary, NC, USA) for data analysis. For continuous variables (i.e. LOS and hospitalization cost) we verified the distribution types by using Kolmogorov-Smirnov test and calculating the coefficients of skewness, and then described their central tendency with mean and 95% confidence interval (95% CI) or median and interquartile range (IQR), as appropriate. The Wilcoxon signed-rank test (W test) was adopted to compare the difference of hospitalization costs between matched pairs of patients. Then a subgroup analysis was performed and the Kruskal-Wallis H test or Mann-Whitney U test were used to identify the heterogeneity of economic losses attributable to HAIs among different medical insurance types, payment systems, infection sites and pathogens. In addition, the Spearman rank correlation coefficient was calculated to analyze the correlation between the prevalence of HAI and investment of its prevention, as well as that between the economic loss and patient’s age. Considering the low power of nonparametric test, the significance level (α) was set to 0.05, not to 0.01, to reduce the probability of false negative errors.

Results

Characteristics of patients

A total of 2976 patients in 10 hospitals (accounting for 12.99% of all tertiary public hospitals in Henan Province) were enrolled, including 7 hospitals with more than 2000 beds. No significant differences were found between the two groups with respect to gender, age, hospitals, aCCI, surgery and admission to ICU (P>0.05; Table 1).
Prevalence of HAI and cost of IPC

The overall incidence rate of HAI in the selected hospitals was 2.42% (range, 0.88% to 4.15%). And the cost of IPC per 1000 beds was $35644.24 (range, $24929.76 to $53146.41), which was significantly, but negatively, associated with the incidence rate of HAI (Spearman r=-0.76, P=0.03).

LOS and hospitalization cost

The length of hospital environment exposure prior to the onset of HAI was 8 days (IQR, 3 to 12 days). And the LOS of HAI group was 23 days, which was 10 days (IQR, 8 to 16 days) significantly longer than that of control group (Table 1). The per patient hospitalization cost in HAI group was $2047.07 higher than that in control group. Among hospitalization cost types, the gap of pharmaceutical cost between two groups ranked top with $1044.39 (excess antimicrobial drug cost accounted for 59.77%; Table 2).

Correlation between economic loss and age

The hospitalization cost of HAI patients were significantly higher than that of control patients on the corresponding age levels, and there existed a significant correlation between the economic loss attributable to HAIs and age (Spearman r=0.26; Table 3).

Economic losses stratified by medical insurance types and payment systems

The differences of economic losses attributable to HAIs among the subgroups of different medical insurance types had marginal statistical significance (P=0.03), and the economic losses in the subgroup of CMI, UEBMI and URBMI were $1834.47, $643.28 and $223.49 higher than the overall median loss, respectively (Table 4). Furthermore, these losses in three different medical insurance payment systems had significant difference (P<0.05), too. The economic losses in the subgroup of SD-PS and DRGs-PS were $1135.42 and $1463.63 lower than the overall median loss, respectively (Table 4).

Economic losses stratified by infection sites

Except the skin and soft tissue, the differences of hospitalization costs between patients with HAI in different infection sites and control group were statistically significant. And the most economic losses attributable to HAIs occurred in the hematologic system ($4734.20) and nervous system ($4197.49). In addition, it was worth noting that the economic losses caused by VAP and CAUTI were 4.14 and 2.87 times significantly higher than those caused by the other HAIs of the respiratory system and urinary system, respectively (Table 5).

Economic losses stratified by pathogens

A total of 568 (38.17%) clinical isolates of pathogens were cultured from patients with HAI, and Escherichia coli (18.13%) was the most frequently isolated bacterial, followed by Acinetobacter baumannii (12.68%) and Klebsiella pneumoniae (11.27%). The economic losses attributable to HAIs caused by different pathogens had statistical significance, of which Acinetobacter baumannii was on the
top list with $9882.75. In addition, the economic losses caused by CRE, CRPa, MRSA and CRAb were 4.06, 3.64, 3.02 and 1.45 times significantly higher than those caused by CSE, CSPa, MSSA and CSAb, respectively (Table 6).

Discussion

To our knowledge, this retrospective study is the first to estimate the current economic burden and analyze the health economic characteristics of HAIs in tertiary public hospitals of Central China. In this work, the estimated economic losses attributable to HAIs was $2047.07, accounting for 28.00% of per capita GDP ($7310.79) and 63.94% of per capita disposable income ($3201.68) in Henan Province, 2018 [8], which is both higher than that of a retrospective survey conducted by Jia HX et al. on 68 general hospitals in China, 2015 [12] and a research did in a referral hospital of Iran, 2017 [13], but lower than the direct economic loss of HAIs estimated by Li H et al. in 5 tertiary public hospitals of Hubei Province, 2016 [14] and that of a similar study made in tertiary hospitals of German, 2015 [15]. On the one hand, it is because the sample size and survey region vary among these studies. On the other hand, by assuming that the economic variables related to hospitalization obey the normal distribution, most of the existing studies used mean as the statistical indicator to describe the central tendency of their distributions [16–17]. Nevertheless, the variables of hospitalization cost and economic loss in our study did not obey the normal distribution, which skewed to the right with a heavy tail, so the statistical indicator of median (lower and upper quartile) was adopted to estimate the economic loss.

In accordance with the results of current researches [17–29], the subgroup analysis shows that the economic losses caused by VAP and CAUTI were approximately 3 to 4 times higher than those caused by the other HAIs of their corresponding systems, while marginal difference was found when it comes to CLABSI, probably because of the limited sample size and low power of U test. We also found that the economic loss attributable to HAIs came mainly from pharmaceutical cost, of which additional antimicrobial drug cost accounted for about 60%. It could be explained by the fact, that antimicrobial drugs are needed to fight against infections, but along with physician's prescription comes the irrational use of antimicrobial drugs (i.e., using drug under no indication of infection, excessive dosage and overlong duration of treatment) [20], which is an independent risk factor for antimicrobial resistance [21–22]. Meanwhile, the infection of Multiple Drug Resistant Organism (MDRO) not only causes huge economic losses, as our study and other relevant studies [23–24] show, but also increases the irrational and inappropriate use of antimicrobial drugs [24]. Infection and antimicrobial resistance complement each other and come to a vicious circle. Therefore, the result of our study is precisely a reminder of the importance of monitoring drug prescription and controlling drug abuse for the reduction of medical burden and the prevention of MDRO infection.

In addition, this study provides the first estimate of the HAI burden on patients with different medical insurance types and payment systems, which indicated that, the HAIs occurred in patients who had CMI, UEBMI or URBMI caused huge waste of healthcare resources. It was not surprising, given that the HSIs-PS is still covering most cities of Henan Province. Under this system, the excess hospitalization cost caused
by HAI are mostly payed for by the medical insurance institutions and a small remaining part by the patients themselves, while the hospitals do not bear the burden basically. As the result of this study showed, the economic losses attributable to HAI in HSIs-PS were almost 5 times higher than those in DRGs-PPS, which quantifies payment criteria of different diagnosis related groups classified by the complexity of diseases and thus limits the waste of medical resources to some extent. Therefore, some developed countries strongly support the investment of HAI prevention by the medical insurance funds [25], and have established some lists of specific HAI that are referred to as “no tolerance” events, thereby reducing the reimbursements to hospitals [26–27].

Our study has several limitations. Considering that the economic burden of HAI includes direct loss of prolonged stay, anti-infection treatment and readmission, as well as the indirect loss which mainly consists of the reduced working hours of family members due to hospital care and the declined labor capacity of patients themselves due to infection and even disability, the total losses attributable to HAI were underestimated in our research. Moreover, although we confirmed that there was a remarkable negative correlation between the incidence rate of HAI and the cost of its prevention, the cause-and-effect relationship between them cannot be proven by this retrospective case-control study. Further prospective studies are needed to address this issue and validate the importance of maintaining the ongoing financial investments in HAI prevention and control.

In conclusion, based on a large, retrospective and Henan province population–based surveillance, our study demonstrates that HAI lead to a great economic loss in tertiary public hospitals of Central China, while reveals the opportunities for easing this burden exist in several areas, including that strengthening the antibiotic stewardship and practicing effective bundle of HAI prevention for patients carrying high risk factors, for example, elders or those with catheterizations in healthcare institutions, and accelerating the medical insurance payment system reform based on DRGs by policy-making departments.

**Appendix**

(1) Hospitalization cost = the total medical expenses incurred by all hospitalized patients (cost of pharmaceutical + operation + lab test + treatment + examination + blood transfusion + material + bed + nursing care).

And the hospitalization cost per patient = hospitalization cost / the total number of hospitalized patients during this period.

(2) IPC cost = daily expenses of IPC office + labor cost of full-time and part-time IPC staff + occupational exposure management expenses + NISS maintenance fee + microbiological monitoring fee of hospital environment + cost of IPC trainings + costs of attending and organizing seminars and academic conferences related to IPC.

(3) The economic loss attributable to HAI = the hospitalization cost of patient with HAI - the hospitalization cost of the corresponding patient in control group.
Abbreviations

HAI: Healthcare-associated infection; DRGs: Diagnosis Related Groups; HICs: High-income countries; LMICs: Low- and Middle-income countries; GDP: Gross Domestic Product; aCCI: age-adjusted Charlson Comorbidity Index; ICD: International Classification of Diseases; LOS: Length of stay; NISS: Nosocomial infections surveillance system; IPC: Infection prevention and control; CI: Confidence Interval; IQR: Interquartile range; ICU: Intensive care unit; CMI: Commercial medical insurance; UEBMI: Urban employee basic medical insurance; URBMI: Urban resident basic medical insurance; NRCMI: New rural cooperative medical insurance; HSI-PS: Healthcare service items-payment system; SD-PS: Single disease-payment system; DRGs-PPS: Diagnosis Related Groups-prospective payment system; CLABSI: Central line-associated bloodstream infection; VAP: Ventilator-associated pneumonia; CAUTI: Catheter-associated urinary tract infection; CRE: Carbapenem-resistant Enterobacteriaceae; CRAb: Carbapenem-resistant A. baumannii; CRPa: Carbapenem-resistant P. aeruginosa; MRSA: Methicillin-resistant S. aureus, while S is short for susceptible in CSE, CSPa, MSSA and CSAb; MDRO: Multiple Drug Resistant Organism

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent for publication was obtained from all participants.

Availability of data and materials

All data analyzed during the study are included in the Tables 1–6.

Competing interests

The authors have declared no conflict of interest.

Funding

This work was supported by the Science and Technology Key Project of Henan Province [grant number 162102310017] and the Health Commission of Henan Province [grant number LHGJ 20190621].

Authors' contributions

The couple of LY and BJZ for literature search, LP, ZYJ and YRX for data analysis, SMJ for policy advice, LP for manuscript drafting and all authors for study design and result interpretation.

Acknowledgements
We are grateful to the Centers for Nosocomial Infection Management and Quality Control of the included cities for research support. And the thanks are given especially to the infection control personnel of all selected hospitals for data collecting and collating after their busy time at fighting against the COVID-19 epidemic.

References

1. Dennis LK, Anthony SF. Harrison's Infectious Diseases, 3/E. McGraw-Hill Medical, 2016.
2. Cassini A, Plachouras D, Eckmanns T, et al. Burden of six healthcare-associated infections on European population health: estimating incidence-based disability-adjusted life years through a population prevalence-based modelling study. PLoS medicine 2016; 13(10): e1002150.
3. Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 2013; 173(22):2039-46.
4. Currie K, Melone L, Stewart S, et al. Understanding the patient experience of health care–associated infection: A qualitative systematic review. American Journal of Infection Control 2018; 46(8):936-942.
5. Kärki T, Plachouras D, Cassini A, et al. Burden of healthcare-associated infections in European acute care hospitals. Wiener Medizinische Wochenschrift 2019; 169:3–5.
6. Marchetti A, Rossiter R. Economic burden of healthcare-associated infection in US acute care hospitals: societal perspective. Journal of Medical Economics 2013; 16(12):1399-1404.
7. Bardossy A C, Zervos J, Zervos M. Preventing hospital-acquired infections in Low-income and Middle-income countries. Infectious Disease Clinics of North America 2016; 30(3):805-818.
8. Henan Statistics Bureau. The Yearbook of Henan Statistics 2019. Beijing: China Statistics Press, 2020.
9. National Health Commission of the People’s Republic of China. Diagnostic Criteria for Nosocomial Infection (in Chinese). http://www.nhc.gov.cn/wjw/gfxwj/201304/37cad8d95582456d8907ad04a5f3bd4c.shtml. Published 2001.
10. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of chronic diseases 1987; 40(5): 373-383.
11. The People’s Bank of China. The announcement of RMB central parity rate. http://www.pbc.gov.cn/zhengcehuobisi/125207/125217/125925/index.html. Accessed March 21, 2020.
12. Jia HX, Hou TY, Li WG, et al. Economic loss due to healthcare-associated infection in 68 general hospitals in China. Chinese journal of infection control 2016; 15(9):637-641.
13. Soleymani F, Palangi HS, Asiabar AS, et al. Costs of hospital-acquired infection for patients hospitalized in intensive care unit of an Iranian referral hospital. Medical journal of the Islamic Republic of Iran 2018; 32(1):388-393.
14. Li H, Liu X, Cui D, et al. Estimating the direct medical economic burden of health care-associated infections in public tertiary hospitals in Hubei Province, China. Asia-pacfic Journal of Public Health 2017; 29(5):440-450.

15. Arefan H, Hagel S, Heublein S, et al. Extra length of stay and costs because of health care–associated infections at a German university hospital. American Journal of Infection Control 2016; 44(2):160-166.

16. Richard EN, Marin LS, Eli NP, et al. Costs and mortality associated with multidrug-resistant healthcare-associated acinetobacter infections. Infection Control and Hospital Epidemiology 2016; 37(10): 1212-1218.

17. Smith DRM, Pouwels KB, Hopkins S, et al. Epidemiology and health-economic burden of urinary-catheter-associated infection in English NHS hospitals: a probabilistic modelling study. Journal of Hospital Infection 2019; 103(1):44-54.

18. Sosa HO, Matías TB, Estrada HA, et al. Incidence and costs of ventilator-associated pneumonia in the adult intensive care unit of a tertiary referral hospital in Mexico. American journal of infection control 2019; 47(9):21-25.

19. Hollenbeak CS, Schilling AL. The attributable cost of catheter-associated urinary tract infections in the United States: A systematic review. American journal of infection control 2018; 46(7): 751-757.

20. Hay SI, Rao PC, Christiane D, et al. Measuring and mapping the global burden of antimicrobial resistance. BMC Medicine 2018; 16(1):78.

21. Nasra D, Iman C, Helene SA, et al. Colonization with multiresistant bacteria in acute hospital care: the association of prior antibiotic consumption as a risk factor. Journal of Antimicrobial Chemotherapy 2020 in press. https://doi.org/10.1093/jac/dkaa365.

22. Zaira RPB, Maddalena G, Davide M, et al. Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review. Clinical Microbiology and Infection 2020 in press. https://doi.org/10.1016/j.cmi.2020.10.016.

23. Woolhouse M, Waugh C, Perry MR, et al. Global disease burden due to antibiotic resistance–state of the evidence. Journal of global health 2016; 6(1): 010306.

24. XJ Lee, AJ Stewardson, LJ Worth, et al. Attributable Length of Stay, Mortality Risk, and Costs of Bacterial Health Care–Associated Infections in Australia: A Retrospective Case-cohort Study. Clinical Infectious Diseases 2020 in press. https://doi.org/10.1093/cid/ciaa1228.

25. Dick AW, Perencevich EN, Pogorzelska-Maziarz M, et al. A decade of investment in infection prevention: A cost-effectiveness analysis. American Journal of Infection Control 2015; 43(1):4-9.

26. Wald HL, Kramer AM. Nonpayment for harms resulting from medical care: catheter-associated urinary tract infections. JAMA 2007; 289: 2782-2784.

27. Cauchi R, Hinkley K, Yondorf B. Great ideas for cutting costs: six more strategies to manage the rising costs of health care. State legislatures 2012; 38(7):28-31.

Tables
Table 1. Description of the included patients
| Variables                              | HAIs                  | Controls               | Z, t or χ² | P         |
|----------------------------------------|-----------------------|------------------------|------------|-----------|
| Male gender, n (%)                     | 888 (59.68)           | 888 (59.68)            | 0          | 1.000     |
| Age, mean in years (95%CI)             | 53 (51, 54)           | 52 (51, 54)            | 0.370<sup>a</sup> | 0.711     |
| Hospitals (anonymized), n (%)          |                       |                        |            |           |
| SY                                     | 352 (23.66)           | 352 (23.66)            | 0          | 1.000     |
| HH                                     | 305 (20.50)           | 305 (20.50)            |            |           |
| ZK                                     | 173 (11.63)           | 173 (11.63)            |            |           |
| ZY                                     | 159 (10.69)           | 159 (10.69)            |            |           |
| ET                                     | 116 (7.80)            | 116 (7.80)             |            |           |
| PD                                     | 101 (6.79)            | 101 (6.79)             |            |           |
| FW                                     | 96 (6.45)             | 96 (6.45)              |            |           |
| XC                                     | 74 (4.97)             | 74 (4.97)              |            |           |
| ZE                                     | 60 (4.03)             | 60 (4.03)              |            |           |
| XX                                     | 52 (3.49)             | 52 (3.49)              |            |           |
| aCCI, n (%)                            |                       |                        |            |           |
| 1                                      | 207 (13.91)           | 205 (13.78)            | 0.372      | 0.999     |
| 2                                      | 231 (15.52)           | 230 (15.46)            |            |           |
| 3                                      | 256 (17.20)           | 266 (17.88)            |            |           |
| 4                                      | 319 (21.44)           | 323 (21.71)            |            |           |
| 5                                      | 305 (20.50)           | 297 (19.96)            |            |           |
| 6                                      | 122 (8.20)            | 119 (8.00)             |            |           |
| ≥7                                     | 48 (3.23)             | 48 (3.23)              |            |           |
| Surgery, n (%)                         | 535 (35.95)           | 535 (35.95)            | 0          | 1.000     |
| Admission to ICU, n (%)                | 417 (28.02)           | 394 (26.48)            | 0.897      | 0.344     |
| LOS, median in days (IQR)              | 23 (15, 36)           | 13 (7, 20)             | 24.277<sup>b</sup> | <0.05     |

Abbreviations: ICU, intensive care unit.

<sup>a</sup> The t value was calculated by using the paired t test.

<sup>b</sup> The standardized Z value was calculated by using W test.
Table 2. The comparison of hospitalization costs between HAI and control groups

| Cost types            | Patients | Median cost ($) | Median loss<sup>c</sup> $; IQR | Z       | P       |
|-----------------------|----------|----------------|---------------------------------|---------|---------|
| Total                 | 2976     | 5838.11        | 2373.52                         | 2047.07 | (327.63, 6429.17) |
| Pharmaceutical        | 2976     | 2546.63        | 973.27                          | 1044.39 | (98.29, 3276.32)  |
| **Antimicrobial drug**| 2938     | 1179.11        | 132.38                          | 624.23  | (73.58, 2466.01)  |
| Operation             | 1642     | 612.97         | 493.44                          | 31.20   | (-15.96, 212.46)  |
| Lab test              | 2944     | 430.17         | 227.55                          | 134.49  | (2.73, 493.84)    |
| Treatment             | 2970     | 382.65         | 134.84                          | 134.69  | (14.40, 513.99)   |
| Examination           | 2880     | 356.56         | 203.79                          | 101.49  | (-22.67, 366.98)  |
| Blood transfusion     | 1082     | 326.53         | 207.58                          | 156.85  | (-14.80, 444.31)  |
| Material              | 2932     | 299.85         | 77.98                           | 70.56   | (-4.40, 518.67)   |
| Bed                   | 2976     | 100.27         | 50.44                           | 37.27   | (1.04, 120.52)    |
| Nursing care          | 2976     | 72.74          | 27.11                           | 26.82   | (2.94, 136.22)    |

<sup>c</sup> Median loss refers to the median of the difference in hospitalization costs between the two groups.

Table 3. Estimates of economic losses attributable to HAIs stratified by age

| Age (years) | Patients | Median loss $; IQR | W test | Correlation |
|-------------|----------|-------------------|--------|-------------|
| ≤1          | 230      | 810.29 (-107.27, 2804.13) | 5.29   | <0.05       |
| 2-5         | 134      | 902.46 (209.86, 2469.87)    | 5.59   | <0.05       |
| 6-20        | 86       | 1711.10 (-371.04, 3948.12)  | 3.83   | <0.05       |
| 21-45       | 368      | 1888.25 (228.63, 7337.86)   | 7.85   | <0.05       |
| 46-65       | 1076     | 1848.80 (154.70, 6433.48)   | 13.85  | <0.05       |
| >65         | 1080     | 2872.57 (810.99, 8116.22)   | 16.74  | <0.05       |

r=0.26, P<0.05
Table 4. Estimates of economic losses attributable to HAIs stratified by medical insurance types and payment systems

| Groups                      | Patients | Median loss ($) (IQR)       | W test | H test     |
|-----------------------------|----------|-------------------------------|--------|------------|
|                             |          |                               | Z      | P          |
| **Medical insurance types** |          |                               |        |            |
| CMI                         | 62       | 3881.55 (2979.70, 5345.27)    | 2.22   | 0.03       |
| UEBMI                       | 366      | 2690.35 (770.94, 7814.00)     | 9.83   | <0.05      |
| URBMI                       | 418      | 2270.56 (36.55, 6790.25)      | 9.62   | <0.05      |
| NRCMI                       | 980      | 1853.68 (248.06, 4848.22)     | 14.52  | <0.05      |
| Self-pay                    | 98       | 1393.82 (334.89, 6827.02)     | 5.21   | <0.05      |
| **Payment systems**         |          |                               |        |            |
| HSIs-PS                     | 2080     | 2857.95 (437.98, 7047.71)     | 21.88  | <0.05      |
| SD-PS                       | 694      | 911.65 (13.53, 3450.14)       | 9.86   | <0.05      |
| DRGs-PPS                    | 202      | 583.44 (197.63, 1811.49)      | 5.22   | <0.05      |

Abbreviations: CMI, commercial medical insurance; UEBMI, urban employee basic medical insurance; URBMI, urban resident basic medical insurance; NRCMI, new rural cooperative medical insurance; HSIs-PS, healthcare service items-payment system; SD-PS, single disease-payment system; DRGs-PPS, diagnosis related groups-prospective payment system.

* With U test, the economic losses in these four subgroups were significantly higher than the overall median loss (P<0.05).
* With U test, the economic losses in these three subgroups were significantly lower than the overall median loss (P<0.05).

Table 5. Estimates of economic losses attributable to HAIs stratified by infection sites
| Infection sites                  | Patients | Median loss ($; IQR) | W or U test | H test |
|----------------------------------|----------|----------------------|-------------|--------|
|                                  |          |                      | Z           | P      |
| Hematologic system               | 77       | 4734.20 (1508.95, 11433.41) | 6.49        | <0.05  |
| CLABSI, n (%)                    | 21 (27.27) | 8323.47 (3036.34, 24773.63) | 1.78f       | =0.08  |
| Nervous system                   | 27       | 4197.49 (1687.76, 7504.14) | 3.82        | <0.05  |
| Lower respiratory tract          | 871      | 2334.44 (422.55, 7695.91) | 19.17       | <0.05  |
| VAP, n (%)                       | 66 (7.58) | 8491.32 (1354.56, 17156.30) | 3.99f       | <0.05  |
| Urinary system                   | 150      | 1933.75 (110.21, 5400.90) | 7.67        | <0.05  |
| CAUTI, n (%)                     | 38 (25.33) | 4687.11 (748.01, 9558.37) | 4.18f       | <0.05  |
| Surgical site                    | 72       | 1825.06 (277.22, 5215.32) | 5.12        | <0.05  |
| Digestive system                 | 81       | 1724.72 (413.08, 3679.93) | 6.03        | <0.05  |
| Skin and soft tissue             | 18       | 1480.67 (354.47, 3284.53) | 1.59        | =0.11  |
| Upper respiratory tract          | 157      | 825.98 (-87.06, 2455.20) | 6.71        | <0.05  |

Abbreviations: CLABSI, central line-associated bloodstream infection; VAP, ventilator -associated pneumonia; CAUTI, catheter-associated urinary tract infection.

f With U test, the economic losses caused by CLABSI, VAP and CAUTI were compared with those caused by the other HAIs of the corresponding system.

Table 6. Estimates of economic losses attributable to HAIs stratified by pathogens
| Pathogens      | Patients | Median loss ($; IQR)       | W or U test | H test       |
|----------------|----------|---------------------------|-------------|--------------|
| E. coli        | 103      | 2386.17 (207.98, 16082.23) | 8.39        | <0.05        |
| K. pneumoniae  | 64       | 5625.70 (1984.14, 39346.78)| 7.42        | <0.05        |
| E. cloacae     | 18       | 3724.49 (491.22, 8170.15)  | 3.59        | <0.05        |
| CRE, n (%)     | 39 (21.08)| 15921.66 (6509.03, 46372.36)| 5.72 g      | <0.05        |
| A. baumannii   | 72       | 9882.75 (4177.74, 22594.55)| 7.90        | <0.05        |
| CRAb, n (%)    | 61 (84.72)| 12436.56 (5627.07, 30927.52)| 7.29 g      | <0.05        |
| P. aeruginosa  | 50       | 6384.40 (2771.56, 12994.86)| 6.51        | <0.05        |
| CRPa, n (%)    | 19 (38.00)| 18250.11 (6982.64, 36036.21)| 4.29 g      | <0.05        |
| S. aureus      | 29       | 4858.02 (1215.62, 13082.85)| 5.07        | <0.05        |
| MRSA, n (%)    | 11 (37.93)| 10680.71 (3926.76,23662.08)| 3.44 g      | <0.05        |
| Enterococcus spp| 36     | 2076.54 (1090.37, 13128.57)| 5.51        | <0.05        |
| C. albicans    | 30       | 4190.53 (837.19, 8871.27)  | 5.11        | <0.05        |
| S. marcescens  | 12       | 2844.62 (334.26, 11937.43) | 3.47        | <0.05        |

Abbreviations: CRE, carbapenem-resistant Enterobacteriaceae; CRAb, carbapenem-resistant A. baumannii; CRPa, carbapenem-resistant P. aeruginosa; MRSA, Methicillin-resistant S. aureus, while S is short for susceptible in CSE, CSPa, MSSA and CSAb.

With U test, the economic losses of HAI caused by CRE, CRAb, CRPa and MRSA were compared with those caused by CSE, CSAb, CSPa and MSSA, respectively.